Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia

von Turecek, Peter L., Johnsen, Jill M., Pipe, Steven W., O'Donnell, James S.
Veröffentlicht in Haemophilia (2020)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Sa...

von Stidl, Reinhard, Denne, Michael, Goldstine, Jimena, Kadish, Bill, Korakas, Katherine I., Turecek, Peter L.
Veröffentlicht in Pharmaceuticals (Basel) (2018)

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibit...

von Brackmann, Hans H., Schramm, Wolfgang, Oldenburg, Johannes, Cano, Viridiana, Turecek, Peter L., Négrier, Claude
Veröffentlicht in Hamostaseologie (2020)

Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura

von Grillberger, Rana, Casina, Veronica C., Turecek, Peter L., Zheng, X. Long, Rottensteiner, Hanspeter, Scheiflinger, Friedrich
Veröffentlicht 2014

A bio-inspired method for direct measurement of local wall shear rates with micrometer localization using the multimeric protein von Willebrand factor as sensor molecule

von Bonazza, Klaus, Scheichl, Bernhard, Frank, Johannes, Rottensteiner, Hanspeter, Schrenk, Gerald, Friedbacher, Gernot, Turecek, Peter L., Scheiflinger, Friedrich, Allmaier, Günter
Veröffentlicht in Biomicrofluidics (2017)

High-dose factor VIII inhibits factor VIII–specific memory B cells in hemophilia A with factor VIII inhibitors

von Hausl, Christina, Ahmad, Rafi U., Sasgary, Maria, Doering, Christopher B., Lollar, Pete, Richter, Günter, Schwarz, Hans Peter, Turecek, Peter L., Reipert, Birgit M.
Veröffentlicht 2005

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

von Dietrich, Barbara, Schiviz, Alexandra, Hoellriegl, Werner, Horling, Frank, Benamara, Karima, Rottensteiner, Hanspeter, Turecek, Peter L., Schwarz, Hans Peter, Scheiflinger, Friedrich, Muchitsch, Eva-Maria
Veröffentlicht in Int J Hematol (2013)

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

von Ferrari, Silvia, Palavra, Kristina, Gruber, Bernadette, Kremer Hovinga, Johanna A., Knöbl, Paul, Caron, Claudine, Cromwell, Caroline, Aledort, Louis, Plaimauer, Barbara, Turecek, Peter L., Rottensteiner, Hanspeter, Scheiflinger, Friedrich
Veröffentlicht 2014

Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage

von Preininger, Alexandra, Schlokat, Uwe, Mohr, Gabriele, Himmelspach, Michèle, Stichler, Veronika, Kyd-Rebenburg, Astrid, Plaimauer, Barbara, Turecek, Peter L., Schwarz, Hans-Peter, Wernhart, Waltraud, Fischer, Bernhard E., Dorner, Friedrich
Veröffentlicht 1999

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

von Turecek, Peter L., Peck, Rachel C., Rangarajan, Savita, Reilly-Stitt, Christopher, Laffan, Michael A., Kazmi, Rashid, James, Izabela, Dushianthan, Ahilanandan, Schrenk, Gerald, Gritsch, Herbert, Ewenstein, Bruce M., Mellgard, Bjorn, Erdlenbruch, Wolfhard, Jain, Nisha, Binder, Nikolaus B., Mumford, Andrew D.
Veröffentlicht in Thromb Res (2021)

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

von Mannucci, Pier Mannuccio, Kempton, Christine, Millar, Carolyn, Romond, Edward, Shapiro, Amy, Birschmann, Ingvild, Ragni, Margaret V., Gill, Joan Cox, Yee, Thynn Thynn, Klamroth, Robert, Wong, Wing-Yen, Chapman, Miranda, Engl, Werner, Turecek, Peter L., Suiter, Tobias M., Ewenstein, Bruce M.
Veröffentlicht 2013